RI-1 is a RAD51 inhibitor with IC50 ranging from 5 to 30 μM.IC50 Value: 5-30 μMTarget: RAD51in vitro: RI-1 sensitizes cells to DNA damage by directly and specifically disrupting HsRAD51 and inhibiting the ability of RAD51 to form filaments on ssDNA. In addition, RI-1 alone generates single-agent toxicity in all three cancer cell lines (HeLa, MCF-7 and U2OS) with LD50 values in the 20–40 μM range. RI-1 decreases the rejoining of γ-H2AX foci in G2 phase cells and results in a higher level of unrepaired DSBs 6 hours after irradiation. in vivo:
CAM833 (CAM-833) is a potent, specific chemical inhibitor of the RAD51-BRCA2 interaction and RAD51 oligomerization with Kd of 366 nM;CAM833 inhibited RAD51 foci formation 6 h after exposure to 3 Gy IR, in a concentration-dependent manner with an IC50 of 6 uM, causeed a concentration-dependent decrease in RAD51 foci accompanied by increased DNA damage in A549 cells.CAM833 inhibted RAD51 molecular clustering at DNA damage sites visualized by SMLM, suppressed homologous recombination and potentiated cell-cycle arrest.CAM833 potentiated the growth suppressive effect of PARP1 inhibition in BRCA2 wild-type cells, as well as dose-dependent growth inhibition when combined with ionizing radiation.
Harmine is a natural dual-specificity tyrosine phosphorylation-regulated kinase ((DYRK)) inhibitor with anticancer and anti-inflammatory activities.
RAD51-IN-3 is a Rad51 inhibitor extracted from patent WO2019051465A1, compound Example 66A[1].
Homologous recombination-IN-1 is a novel RAD51-BRCA2 protein-protein interaction inhibitor (EC50=19 μM). Homologous recombination-IN-1 can interfere with homologous recombination[1].
RS-1 is a RAD51 activator, and also increases CRISPR/Cas9-mediated knock-in efficiencies.
RAD51-IN-17 is a quinazolinone derivative that inhibts homologous recombinase RAD51, effectively inhibits both RAD51 foci formation in response to DNA damage, and proliferation of TNBC cell lines; also sensitizes aggressive metastatic TNBC to DNA damage induced by irradiation; a valuable research tool for developing combination therapies to overcome RAD51 driven resistance and relapse in a variety of cancers.
RAD51-IN-4 is a potent inhibitor of RAD51. RAD51 is a eukaryote gene. RAD51-IN-4 has the potential for the research of conditions involving mitochondrial defects (extracted from patent WO2019014315A1, compound R12)[1].
RAD51 Inhibitor B02 (B02) is an inhibitor of human RAD51 with an IC50 of 27.4 μM.
RI-2 is a reversible RAD51 inhibitor, with an IC50 of 44.17 μM, and specifically inhibits homologous recombination repair in human cells.
RAD51-IN-6 is a potent inhibitor of RAD51. RAD51 is a eukaryote gene. RAD51-IN-6 has the potential for the research of conditions involving mitochondrial defects (extracted from patent WO2021164746A1, compound 23)[1].
RAD51-IN-5 is a potent inhibitor of RAD51. RAD51 is a eukaryote gene. RAD51-IN-5 has the potential for the research of conditions involving mitochondrial defects (extracted from patent WO2021164746A1, compound 3)[1].
DIDS is a potent RAD51 inhibitor. DIDS inhibits the RAD51-mediated homologous pairing and strand-exchange reactions. DIDS inhibits anion exchange and binding to the red blood cell membrane[1][2].
RAD51-IN-2 (compound example 67A) is a RAD51 inhibitor extracted from patent WO2019/051465A1[1].
RAD51-IN-7 is a potent inhibitor of RAD51. RAD51 is a eukaryote gene. RAD51-IN-7 has the potential for the research of conditions involving mitochondrial defects (extracted from patent WO2021164746A1, compound 71)[1].
IBR2 is a specific RAD51 inhibitor.
T0070907 is a potent PPARγ antagonist with a Ki of 1 nM.